Mankind Pharma Q2 Results FY26: Net Profit Falls 22% YoY to Rs 511.5 Crore Despite 21% Revenue Growth

Mankind Pharma Ltd, one of India's leading pharmaceutical companies, reported a decline in its profitability for the quarter ended September 2025, even as revenue showed a strong year-on-year increase.

Mankind Pharma Q2 Results FY 2026: Net Profit Falls 22% YoY Despite 21% Revenue Growth

According to the company's financial results released on Wednesday, Mankind Pharma's consolidated net profit dropped 21.7% year-on-year (YoY) to Rs 511.5 crore, compared to Rs 653.4 crore recorded in the same quarter last year.

Despite the decline in profit, the company's revenue from operations surged by 20.8% YoY to Rs 3,697 crore, up from Rs 3,061 crore in the corresponding period a year ago. The growth in revenue was driven by a robust performance in domestic formulations and strong sales across key therapeutic segments.

At the operating level, earnings before interest, tax, depreciation, and amortization (EBITDA) stood at Rs 921.8 crore, reflecting an 8.8% YoY increase from Rs 847.5 crore in Q2 FY25. However, the company's EBITDA margin contracted to 24.9% from 27.7% in the year-ago quarter, indicating rising input costs and competitive pricing pressures in the pharmaceutical market.

Mankind Pharma Share Price Today Ahead of Q2 Earnings FY26

Shares of Mankind Pharma Ltd closed lower on Thursday, November 6, 2025, ending the trading session at Rs 2,310.00, down Rs 59.50 or 2.51% for the day. During the session, the stock opened at Rs 2,375.00, touched an intraday high of Rs 2,379.80, and hit a low of Rs 2,305.30 on the NSE.

Disclaimer

The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.